Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Gilead Sciences Inc
GILD
Healthcare
Biotechnology
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products...
includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, and Domvanalimab and zimberelimab, and seladelpar. Seladelpar shall be used for the treatment of primary biliary cholangitis (PBC), including pruritus. The Company operates in more than 35 countries.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:GILD)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
Next
(279)
•••
whytestocks
X
Post by
whytestocks
on Jul 22, 2024 4:19am
Gilead and the Elton John AIDS Foundation Announce Additiona
Just In: $GILD Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership to Help Address the Growing HIV Crisis in Eastern Europe and Central Asia@ RADIAN@s Five
...more
(279)
•••
whytestocks
X
Post by
whytestocks
on Jun 20, 2024 1:30pm
Biotechs Race to Develop New Treatments as Global Pancreatic
NEWS: $GILD Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 20332024-06-20 08:45:59 ET Palm Beach, FL @ June 20, 2024 
...more
(279)
•••
whytestocks
X
Post by
whytestocks
on Jun 14, 2024 4:45pm
Outperform Recommendation Issued On GILD By Evercore ISI
BREAKING NEWS: $GILD Outperform Recommendation Issued On GILD By Evercore ISI2024-06-14 15:15:06 ET Evercore ISI analyst issues OUTPERFORM recommendation for GILD on June 14, 2024 11:39AM ET. The
...more
(279)
•••
whytestocks
X
Post by
whytestocks
on Jun 14, 2024 4:30pm
Sector Perform Recommendation Issued On GILD By UBS
News; $GILD Sector Perform Recommendation Issued On GILD By UBS2024-06-14 15:15:06 ET UBS analyst issues SECTOR PERFORM recommendation for GILD on June 14, 2024 12:00PM ET. The previous analyst
...more
(279)
•••
whytestocks
X
Post by
whytestocks
on Jan 22, 2024 6:45pm
Why Gilead Sciences Stock Got Mashed on Monday
JUST IN: $GILD Why Gilead Sciences Stock Got Mashed on Monday2024-01-22 18:08:02 ET Pharmaceutical sector mainstay Gilead Sciences (NASDAQ: GILD) has had many good days on the stock exchange, but
...more
(279)
•••
whytestocks
X
Post by
whytestocks
on Jan 22, 2024 6:30pm
Gilead Provides Update on Phase 3 EVOKE-01 Study
JUST IN: $GILD Gilead Provides Update on Phase 3 EVOKE-01 StudyGilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall
...more
(279)
•••
whytestocks
X
Post by
whytestocks
on Jul 14, 2023 3:00pm
FDA Approves Veklury® (Remdesivir) for COVID-19 Treatme
NEWS: $GILD FDA Approves Veklury® (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis-- Veklury is Now the First Approved Antiviral
...more
(0)
•••
Peng26
X
Post by
Peng26
on Apr 13, 2023 5:19am
Kevin Harrington Speaks about FSD Pharma
FSD Pharma Inc is about to launch this breakthrough product!!
(1)
•••
Rebecca
X
Post by
Rebecca
on Apr 13, 2023 3:13am
Kevin Harrington Discusses FSD Pharma
I believe this new product will aid society in reducing the
...more
(3)
•••
jonathanS
X
Post by
jonathanS
on Aug 03, 2022 9:15am
roughly $80 billion biopharmaceutical company
The wide array of offerings helps fuel consistent payouts to shareholders. Current distributions are 73 cents per quarter, up 70% from 43 cents a share back at the beginning of 2016 and proof that
...more
(1)
•••
Rebecca
X
Post by
Rebecca
on Jul 15, 2022 8:49pm
FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent
(1)
•••
Rebecca
X
Post by
Rebecca
on Jun 03, 2022 4:19am
FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance
(1)
•••
Rebecca
X
Post by
Rebecca
on Jun 01, 2022 11:54pm
FSD Pharma Files Investigational New Drug Application “IND”
(1)
•••
Rebecca
X
Post by
Rebecca
on May 10, 2022 11:55pm
FSD Pharma Closes CAD$16.4 Million Sale of Non-Core Assets
(1)
•••
Rebecca
X
Post by
Rebecca
on May 03, 2022 9:45pm
Lucid-MS for Multiple Sclerosis Treatment
Prev
1
2
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Introducing the NEW DealRoom: Your Gateway to Capital-Raising Investments
Are PGM mining stocks an attractive area for your next portfolio allocation?
ReGen III Appoints New CEO and President to Accelerate Commercial and Strategic Opportunities